150 related articles for article (PubMed ID: 17102944)
1. Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis.
Sánchez G; Castro JS; Snih SA; Blanco LP; Esteva MH; Macgregor EG; González M; Granados Y; Marín F; Rosas A; Tristano A; Chirinos E; Mundaraín L; Sanoja G; Zambrano-Marín G; Rodríguez MA
Rheumatol Int; 2007 Apr; 27(6):531-6. PubMed ID: 17102944
[TBL] [Abstract][Full Text] [Related]
2. [Security of the combined treatment of methotrexate and leflunomide in patients with rheumatoid arthritis].
Nesa L; Gobbi C; Alba P; Exeni I; Babini A; Albiero E
Rev Fac Cien Med Univ Nac Cordoba; 2007; 64(4):109-14. PubMed ID: 19928400
[TBL] [Abstract][Full Text] [Related]
3. The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritis.
Bird P; Griffiths H; Tymms K; Nicholls D; Roberts L; Arnold M; Burnet S; de Jager J; Scott J; Zochling J; Littlejohn G
J Rheumatol; 2013 Mar; 40(3):228-35. PubMed ID: 23322457
[TBL] [Abstract][Full Text] [Related]
4. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
5. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate.
Wolfe F; Michaud K; Stephenson B; Doyle J
J Rheumatol; 2003 Aug; 30(8):1725-32. PubMed ID: 12913927
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011?
Singer O; Gibofsky A
Curr Opin Rheumatol; 2011 May; 23(3):288-92. PubMed ID: 21378570
[TBL] [Abstract][Full Text] [Related]
7. [Can a combination therapy with leflunomide be recommended for patients with active rheumatoid arthritis?].
Hamann F
Z Rheumatol; 2003 Apr; 62(2):204-5. PubMed ID: 12820624
[No Abstract] [Full Text] [Related]
8. Efficacy of leflunomide 100mg weekly compared to low dose methotrexate in patients with active rheumatoid arthritis. Double blind, randomized clinical trial.
Jaimes-Hernández J; Meléndez-Mercado CI; Mendoza-Fuentes A; Aranda-Pereira P; Castañeda-Hernández G
Reumatol Clin; 2012; 8(5):243-9. PubMed ID: 22763150
[TBL] [Abstract][Full Text] [Related]
9. Influence of MTHFR C677T polymorphism on methotrexate monotherapy discontinuation in rheumatoid arthritis patients: results from the GAPAID European project.
Uribarri M; Ruiz-Larrañaga O; Arteta D; Hernández L; Alcaro MC; Martínez A; Escorza-Treviño S; Estonba A; Migliorini P; Czirják L; del Amo J
Clin Exp Rheumatol; 2015; 33(5):699-705. PubMed ID: 26314492
[TBL] [Abstract][Full Text] [Related]
10. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
[TBL] [Abstract][Full Text] [Related]
11. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.
Bao C; Chen S; Gu Y; Lao Z; Ni L; Yu Q; Xu J; Li X; Liu J; Sun L; He P; Ma J; Xu S; Ding C
Chin Med J (Engl); 2003 Aug; 116(8):1228-34. PubMed ID: 12935395
[TBL] [Abstract][Full Text] [Related]
12. Liver toxicity is rare in rheumatoid arthritis patients using combination therapy with leflunomide and methotrexate.
Alves JA; Fialho SC; Morato EF; Castro GR; Zimmermann AF; Ribeiro GG; Neves FS; Pereira IA
Rev Bras Reumatol; 2011; 51(2):141-4. PubMed ID: 21584420
[TBL] [Abstract][Full Text] [Related]
13. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.
van der Kooij SM; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; van Zeben D; Kerstens PJ; Gerards AH; van Groenendael JH; Hazes JM; Breedveld FC; Allaart CF; Dijkmans BA
Ann Rheum Dis; 2007 Oct; 66(10):1356-62. PubMed ID: 17293364
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy.
Stamp LK; O'Donnell JL; Chapman PT; Zhang M; James J; Frampton C; Barclay ML
Arthritis Rheum; 2010 Feb; 62(2):359-68. PubMed ID: 20112376
[TBL] [Abstract][Full Text] [Related]
15. Severe leukopenia in a rheumatoid arthritis patient treated with a methotrexate/leflunomide combination.
Toth P; Bernd R
Rev Bras Reumatol; 2014; 54(2):152-4. PubMed ID: 24878863
[TBL] [Abstract][Full Text] [Related]
16. [Drug therapy and malpractice exemplified by combination leflunomide and methotrexate therapy].
Burgardt C
Z Rheumatol; 2002 Apr; 61(2):189-90. PubMed ID: 12056298
[No Abstract] [Full Text] [Related]
17. Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis.
Rodriguez-Rodriguez L; Jover-Jover JA; Fontsere O; Peña-Blanco RC; León L; Fernández-Gutierrez B; Abásolo L
Scand J Rheumatol; 2013; 42(6):433-6. PubMed ID: 23742043
[TBL] [Abstract][Full Text] [Related]
18. Influence of methotrexate on gastrointestinal symptoms in patients with rheumatoid arthritis.
Asai S; Nagai K; Takahashi N; Watanabe T; Matsumoto T; Asai N; Sobue Y; Ishiguro N; Kojima T
Int J Rheum Dis; 2019 Feb; 22(2):207-213. PubMed ID: 30168274
[TBL] [Abstract][Full Text] [Related]
19. [Leflunomide + methotrexate combination therapy from the physician's viewpoint].
Reinhold-Keller E; Gromnica-Ihle E
Z Rheumatol; 2002 Apr; 61(2):191-3. PubMed ID: 12056299
[No Abstract] [Full Text] [Related]
20. Longterm retention rate and risk factor for discontinuation due to insufficient efficacy and adverse events in Japanese patients with rheumatoid arthritis receiving etanercept therapy.
Matsubara H; Kojima T; Kaneko A; Hirano Y; Ishikawa H; Hattori Y; Miyake H; Oguchi T; Takagi H; Yabe Y; Kato T; Ito T; Fukaya N; Kanayama Y; Shioura T; Hayashi M; Fujibayashi T; Takahashi N; Funahashi K; Kato D; Hanabayashi M; Terabe K; Ishiguro N
J Rheumatol; 2014 Aug; 41(8):1583-9. PubMed ID: 25028370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
